Drug intelligence / Profile preview

AVI-102

Development stage: Preclinical
Lead developer: AbVision
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AVI-102 is a preclinical **monoclonal antibody** immuno-oncology candidate from **AbVision** for **cancer**. It is an anti-human **PD-1** antibody designed to block the programmed cell death protein 1 checkpoint pathway, thereby enhancing anti-tumor T-cell responses through **PD-1 immune checkpoint blockade**. The molecule was generated using AbVision's SpeedyAb technology platform and has been described by the company as available for out-licensing to support downstream development and clinical evaluation.

Other names: Anti-PD-1Anti-PD1Anti-PD 1

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on AVI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI-102.

Explore the full profile